Veradermics raised $256.3 million in an upsized IPO on February 4, 2026, selling 15.1 million shares at $17 per share, above the expected range of $14-$16.135
The IPO priced higher than anticipated, with shares soaring 122% to close at $137.65 on debut, signaling strong investor demand.2
Proceeds will fund Phase II/III clinical trials for VDPHL-01, an oral, non-hormonal extended-release minoxidil formulation for pattern hair loss in men and women.123
The New Haven, CT-based company, founded in 2019, trades on the NYSE under ticker MANE and targets FDA approval via 505(b)(2) NDA.23
Pattern hair loss affects ~50 million men and 30 million women in the US, representing a $9 billion market opportunity.23
Anchor investors included Wellington Management ($30M) and Eli Lilly (4.9% of shares).3
Sources:
1. https://www.bioworld.com/articles/728557-hair-loss-drugmaker-veradermics-floats-upsized-256m-us-ipo
2. https://news.crunchbase.com/public/veradermics-shares-soar-in-ipo/
3. https://www.renaissancecapital.com/IPO-Center/News/116715/Hair-loss-biotech-Veradermics-prices-upsized-IPO-at-$17-above-the-range
5. https://www.streetinsider.com/Equity+Offerings/Veradermics+prices+upsized+IPO+at+$17+per+share,+raising+$256.3+million/25941462.html